The plasmid DNA manufacturing market size is poised to grow by $ 2,156.58 million by 2032 from $ 446.13 million in 2022, exhibiting a CAGR of 21.7% during the forecast period 2022 to 2030.
Key Takeaway:
- The pre-clinical therapeutics development phase segment is expected to grow at a CAGR of 14.3%.
- The cell & gene therapy application segment has held market share of 59% in 2022.
- The cancer disease segment has captured market share of 37.5% in 2022.
- The GMP grade segment has reached highest revenue share of 88.4% in 2022.
- The North America region has dominated the market with revenue share of 49.5% in 2022.
The main objective of this report is to define, describe, and forecast the global market by types, application, manufacturers, and regions. The report provides detailed information about the major factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the market. The report aims to strategically analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global market. The report also attempts to forecast the market size of the 5 main regions: North America, Europe, Asia Pacific (APAC), Middle East and Africa (MEA), and Latin America. It strategically profiles the key market players and comprehensively analyzes their core competencies. It also tracks and analyzes competitive developments, such as joint ventures, mergers and acquisitions, new developments, and Research and Development (R&D) activities, in market.
Get a Sample: https://www.precedenceresearch.com/sample/1299
COVID-19 Impact
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the electric vehicle fuel cell market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Major companies operating in this area
- VGXI, Inc.
- Akron Biotech
- Cobra Biologics & Pharmaceutical Services
- Aldevron
- Plasmidfactory GmbH
- Vigene Biosciences
- Luminous Biosciences
- Nature Technology Corporation
- Delphi Genetics
- JAFRAL Ltd.
Market Segmentation
By Product
- Viral Vectors
- Plasmid DNA
- Non-Viral
- Electroporation
- Lipid/Polymer
- Nanoparticles
- Others
By Application
- Gene Therapy
- DNA Vaccines
- Immunotherapy
- Others
By Disease
- Infectious Disease
- Genetic Disorder
- Cancer
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of the World
Major highlights of Report:
- Figures related to sales volume, market remuneration, and segmental shares
- Featuring market dynamics
- Growth prospects and expansion graph
- PROCON study of direct & indirect sales channels
- Profiles of prominent traders, dealer, and distributors in the industry
Geographical landscape: North America, Europe, Asia-Pacific, South America, Middle East and Africa
- Industry forecasts based on region and at country level
- Data about sales volume recorded, industry share held, and profit margins amassed
- Overall remuneration and estimated growth rate for each regional market
Major Key Points Covered in Report:
Executive Summary: It includes key trends of the electric vehicle fuel cell market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the electric vehicle fuel cell market based on production and revenue.
Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.
Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Electric vehicle fuel cell market.
Market Segments: This part of the report discusses product, application and other segments of the electric vehicle fuel cell market based on market share, CAGR, market size, and various other factors.
Research Methodology: This section discusses the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Plasmid DNA Manufacturing Market, By Product
7.1. Plasmid DNA Manufacturing Market, by Product Type, 2021-2030
7.1.1. Viral Vectors
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Plasmid DNA
7.1.2.1. Market Revenue and Forecast (2019-2030)
7.1.3. Non-Viral
7.1.3.1. Market Revenue and Forecast (2019-2030)
7.1.4. Electroporation
7.1.4.1. Market Revenue and Forecast (2019-2030)
7.1.5. Lipid/Polymer
7.1.5.1. Market Revenue and Forecast (2019-2030)
7.1.6. Nanoparticles
7.1.6.1. Market Revenue and Forecast (2019-2030)
7.1.7. Others
7.1.7.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Plasmid DNA Manufacturing Market, By Application
8.1. Plasmid DNA Manufacturing Market, by Application, 2021-2030
8.1.1. Gene Therapy
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Immunotherapy
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Plasmid DNA Manufacturing Market, By Disease
9.1. Plasmid DNA Manufacturing Market, by Disease, 2021-2030
9.1.1. Infectious Disease
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Genetic Disorder
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Cancer
9.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.3. Market Revenue and Forecast, by Disease (2019-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.6.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.7.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.7.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.6.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.7.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.7.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.6.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.7.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.7.3. Market Revenue and Forecast, by Disease (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.5.3. Market Revenue and Forecast, by Disease (2019-2030)
Chapter 11. Company Profiles
11.1. VGXI, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Akron Biotech
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Cobra Biologics & Pharmaceutical Services
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Aldevron
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Plasmidfactory GmbH
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Vigene Biosciences
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Luminous Biosciences
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Nature Technology Corporation
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Delphi Genetics
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. JAFRAL Ltd.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments